To be considered for funding, applications for the FY22 PCARP Translational Research Partnership Award must address at least one of the FY22 PCARP Focus Areas:
- Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities
- Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during treatment and survivorship
- Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia
- Understanding precursors, origins, and early progression of pancreatic cancer
- Understanding the events that promote pancreatic cancer metastasis
- Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
- New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
The anticipated direct costs budgeted for the entire period of performance for an FY22 Pancreatic Cancer Translational Research Partnership Award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.